Skip to contentI
INSMED Inc
I
INSMINSMED Inc Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$104.44M$104.44Mderived+24.8% vs Q4 2023 Net Income-$235.55M-$235.55MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
INSMED Inc · CIK 1104506 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$230,414,000N/M Operating Cash Flowderived-$195,979,000N/M Free Cash Flowderived-$202,751,000N/M Margins · derivedOperating margin-220.6%−7.6 pt vs Q4 2023
Net margin-225.5%−3.2 pt vs Q4 2023
ended Dec 31, 2024 · filed Feb 20, 2025 · 51 d after period end